Daniel Delitto

Daniel Delitto

Auto-generated profile, based on publicly available information

Daniel Delitto

University of Florida, Gainesville, FL

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2015 in BMC Cancer
Verified
Journal Article
Open access
PDF file
DDDaniel Delitto
Daniel Delitto
BBBrian S. Black
Brian S. Black
HSHeather L. Sorenson
Heather L. Sorenson
AKAndrea E. Knowlton
Andrea E. Knowlton
RTRyan M. Thomas
Ryan M. Thomas
SHSteven J. Hughes
Steven J. Hughes
The tumor microenvironment impacts pancreatic cancer (PC) development, progression and metastasis. How intratumoral inflammatory mediators modulate this biology remains poorly understood. We hypothesized that the inflammatory milieu within the PC microenvironment would correlate with clinicopathologic findings and survival. Pancreatic specimens from normal pancreas (n = 6), chronic pancreatitis (n = 9) and pancreatic adenocarcinoma (n = 36) were homogenized immediately upon resection. Homogenates were subjected to multiplex analysis of 41 inflammatory mediators. Twenty-three mediators were significantly elevated in adenocarcinoma specimens compared to nonmalignant controls. Increased intratumoral IL-8 concentrations associated with larger tumors (P = .045) and poor differentiation (P = .038); the administration of neoadjuvant chemotherapy associated with reduced IL-8 concentrations (P = .003). Neoadjuvant therapy was also associated with elevated concentrations of Flt-3 L (P = .005). Elevated levels of pro-inflammatory cytokines IL-1β (P = .017) and TNFα (P = .033) were associated with a poor histopathologic response to neoadjuvant therapy. Elevated concentrations of G-CSF (P = .016) and PDGF-AA (P = .012) correlated with reduced overall survival. Conversely, elevated concentrations of FGF-2 (P = .038), TNFα (P = .031) and MIP-1α (P = .036) were associated with prolonged survival. The pancreatic cancer microenvironment harbors a unique inflammatory milieu with potential diagnostic and prognostic value.

1 October 2014 in Journal of the American College of Surgeons
Verified
Journal Article
Closed access
DDDaniel Delitto
Daniel Delitto
SHSong Han
Song Han
SHSteven J. Hughes
Steven J. Hughes
KBKevin E. Behrns
Kevin E. Behrns
JTJose G. Trevino
Jose G. Trevino

1 January 2016
Verified
Book Chapter
Closed access
PDF file
DDDaniel Delitto
Daniel Delitto
KBKevin E. Behrns
Kevin E. Behrns

1 April 2018 in Laparoscopic Surgery
Verified
Journal Article
Open access
PDF file
DDDaniel Delitto
Daniel Delitto
SHSteven J. Hughes
Steven J. Hughes

1 February 2017 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
TGThomas J George
Thomas J George
LDLong H. Dang
Long H. Dang
KDKaren Colleen Daily
Karen Colleen Daily
JSJason Scott Starr
Jason Scott Starr
HPHiral D. Parekh
Hiral D. Parekh
Jose TrevinoJose Trevino
Jose Trevino
TPS517 Background: Systemic chemotherapy for pancreatic adenocarcinoma improves survival and cancer related symptoms. Most targeted agents combined with gemcitabine have consistently failed to demonstrate clinical benefits. Src is overexpressed in pancreatic cancer and promotes an aggressive cancer phenotype. Dasatinib (D) is an oral multi-tyrosine kinase inhibitor (TKI) affecting tumor proliferation through inhibition of Src, Bcr-Abl, CKit and other pathways. Inhibition of Src is associated with biologic modifications favorably modifying the pancreatic cancer phenotype and has synergy with restoring inherent chemosensitivity. Src inhibition can also increase oxaliplatin activity and modulate Tcell responses. The addition of D to the well-established backbone of FOLFOX represents a multifaceted line of scientific investigation. Methods: This is a multicenter phase II trial to determine activity and toxicity of FOLFOX + D in previously untreated metastatic pancreatic adenocarcinoma. Eligible pts must have at least 1 measurable target lesion by RECIST, ECOG PS 0-2, normal QTc and adequate organ function. Pts received standard cycles of mFOLFOX6 repeated q14d with continuous D (150mg PO daily). Tumor assessments occur q8w. Endpoints included progression-free survival (primary; PFS), objective and biochemical response rates, clinical benefit rate, freedom from metastases, overall survival (OS), toxicity, and quality of life. Exploratory tissue, circulating tumor cell and serum analyses to identify predictors of response are planned, particularly in those demonstrating durable disease control or exceptional response. Sample size was based on a 50% improved median PFS from 4 (historical) to 6 months. NCT01652976. Results: Enrollment continues on this prospective phase II study with 38 of 42 evaluable patients. There are no unexpected toxicities noted thus far. Clinical trial information: NCT01652976. [Table: see text]

1 May 2018 in Gastroenterology
Verified
Journal Article
Closed access
MGMichael Gerber
Michael Gerber
WGWilliam Gooding
William Gooding
DDDaniel Delitto
Daniel Delitto
JCJessica Cioffi
Jessica Cioffi
BDBayli DiVita
Bayli DiVita
SHSteven J. Hughes
Steven J. Hughes